Roche’s Strategic Pivot Gains Momentum from Immunology and Capital Restructuring
Roche reports strong Phase III lupus data for Gazyva and finalizes share conversion. The company also increased its…
Roche Shares Under Pressure Following Clinical Trial Setback
Roche shares drop after giredestrant fails Phase III breast cancer trial. Analysts diverge on outlook as company pivots…
Roche’s Dividend Milestone Overshadowed by Clinical Trial Setback
Roche’s 39th consecutive dividend increase contrasts with a Phase III trial failure for giredestrant, pressuring shares and clouding…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer](https://www.europesays.com/ch/wp-content/uploads/2026/03/964824-380x220.png)
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival,…
Roche’s Weight-Loss Ambitions Face Reality Check
Roche’s Petrelintide shows 9% net weight loss in Phase II, missing high expectations. Stock and partner Zealand Pharma…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-valueAt the…
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4,…
Asian Investment and Clinical Trial Scrutiny
Roches, Strategic
05.03.2026 – 05:37:28 | boerse-global.de
Roche reports mixed Phase III results for…
Iran Says Nuclear Talks with US in Geneva Enter Detailed Technical Phase
Islam Times – The spokesperson for Iran’s Foreign Ministry said that the new round of Tehran–Washington nuclear negotiations…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1…
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
In ALIGN study, Vanrafia (atrasentan) showed positive differencein eGFR change from baseline vs. placebo at Week 136, 4…